Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Non-peptide delta opioid agonists and antagonists (Part II)
Autore:
Dondio, G; Ronzoni, S; Petrillo, P;
Indirizzi:
SmithKline Beecham SpA, Dept Biol, I-20021 Milan, Italy SmithKline BeechamSpA Milan Italy I-20021 pt Biol, I-20021 Milan, Italy SmithKline Beecham SpA, Res Dept, I-20021 Milan, Italy SmithKline Beecham SpA Milan Italy I-20021 es Dept, I-20021 Milan, Italy
Titolo Testata:
EXPERT OPINION ON THERAPEUTIC PATENTS
fascicolo: 4, volume: 9, anno: 1999,
pagine: 353 - 374
SICI:
1354-3776(199904)9:4<353:NDOAAA>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
DELTA(1)-OPIOID RECEPTOR ANTAGONIST; CENTRAL-NERVOUS-SYSTEM; INTACT RAT-HEART; PHYSICAL-DEPENDENCE; MEDIATED PHENOMENA; LUNG-CANCER; IN-VITRO; MU; INFLAMMATION; MODEL;
Keywords:
delta opioid receptor; delta opioid receptor pharmacology; delta selective agonists/antagonists;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
83
Recensione:
Indirizzi per estratti:
Indirizzo: Dondio, G SmithKline Beecham SpA, Dept Med Chem, I-20021 Milan, Italy SmithKline Beecham SpA Milan Italy I-20021 -20021 Milan, Italy
Citazione:
G. Dondio et al., "Non-peptide delta opioid agonists and antagonists (Part II)", EXPERT OP T, 9(4), 1999, pp. 353-374

Abstract

A continuing effort in the development of non-peptide delta opioid agonists and antagonists has been seen in the last two years. The first non-peptide delta opioid antagonist naltrindole has represented for years the starting point for the design of novel potent and selective delta opioid ligands. Several research groups are still working on the framework of this prototype and have produced a large number of new derivatives with different in vitro and in vivo pharmacological activities. The discovery of TAN-67, BW373U86 and SNC 80 stimulated other lines of research aimed at synthesising analogues with better delta opioid agonist profile and suitable in vivo activity. Chemically unrelated compounds have also been disclosed deriving from thestructural comparison of previously identified ligands. These studies havegiven further insights about the key determinants for the selective interaction with the delta opioid receptor (DOR). The availability of these tool compounds has allowed significant progression in the understanding of the pharmacology associated with the DOR. In addition to the possible use of selective delta opioid agonists as safe and effective pain relief agents, other interesting activities of possible clinical interest have been disclosed e.g., antiviral, cardioprotective and diuretic activity. Furthermore, many scientific reports confirmed the interesting pharmacological activities associated to the selective blockade of the DOR with antagonists e.g., immunosuppression and prevention of substance abuse. This review will focus on theabove research activities, highlighting the most relevant literature and patent reports of the last two years. The medicinal chemistry and the competitive scenario related to non-peptide delta opioid ligands will be considered. Emphasis on the therapeutic potential of selective delta opioid ligandswill also be discussed throughout the present review.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 18:51:40